Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 2/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19681207 | 0.86 | MMP3 (0.46) | F2ITGB1ITGA4NPSR1APLNR | |
| SCHEMBL21166989 | 0.85 | ACE (0.45) | F2ITGB1ITGA4RENAPLNR | |
| SCHEMBL19685305 | 0.85 | P2RX7 (0.48) | F2P2RX7TNKSNPSR1 | |
| SCHEMBL19677781 | 0.84 | MEN1 (0.45) | NPSR1APLNR | |
| SCHEMBL21705595 | 0.83 | F2 (0.46) | F2P2RX7ITGB1ITGA4TNKS | |
| SCHEMBL21350914 | 0.83 | ITGB1 (0.42) | F2P2RX7ITGB1ITGA4REN | |
| SCHEMBL21166966 | 0.83 | ITGB1 (0.44) | F2ITGB1ITGA4RENAPLNR | |
| SCHEMBL19681283 | 0.83 | APLNR (0.44) | F2P2RX7NPSR1APLNRMMP1 | |
| SCHEMBL21346666 | 0.82 | REN (0.54) | REN | |
| SCHEMBL19681253 | 0.81 | SIRT6 (0.52) | F2NPSR1APLNRMMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707507-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | ADOCIA (FR) | 2023-07-25 | — | — | US | disclosed |
| US-20200306346-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2020-10-01 | — | — | US | disclosed |
| US-20200046805-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2020-02-13 | — | — | US | disclosed |
| US-10548952-B2 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2020-02-04 | — | — | US | disclosed |
| US-10463717-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | ADOCIA (FR) | 2019-11-05 | — | — | US | disclosed |
| US-20190274953-A1 | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275108-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275110-A1 | COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-10383918-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid | ADOCIA (FR) | 2019-08-20 | — | — | US | disclosed |
| US-10383920-B2 | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2019-08-20 | — | — | US | disclosed |
| US-20180193421-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2018-07-12 | — | — | US | disclosed |
| US-20170348394-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170348395-A1 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170348423-A1 | Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170348396-A1 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275108-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | IAPP, GPR119, GLP1R | F2 2492/4885P2RX7 519/4885ITGB1 3012/4885 |
| US-20180193421-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | IAPP, GPR119, GIPR | F2 2618/4885P2RX7 573/4885ITGB1 3307/4885 |
| US-10463717-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | IAPP, GPR119, GIPR | F2 2863/4885P2RX7 446/4885ITGB1 3317/4885 |
| US-20200306346-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GLP1R, GCGR | F2 464/4885P2RX7 1969/4885ITGB1 4390/4885 |
| US-20200046805-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | IAPP, INSR, GLP1R | F2 812/4885P2RX7 870/4885ITGB1 3493/4885 |
| US-20170348423-A1 | Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, IDE, INSR | F2 937/4885P2RX7 2698/4885ITGB1 2716/4885 |
| US-20170348394-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID | GCG, GLP1R, IAPP | F2 317/4885P2RX7 2375/4885ITGB1 3569/4885 |
| US-10383918-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid | GCG, GLP1R, IAPP | F2 317/4885P2RX7 2375/4885ITGB1 3569/4885 |
| US-20190275110-A1 | COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GLP1R, IAPP | F2 305/4885P2RX7 2322/4885ITGB1 4124/4885 |
| US-20170348395-A1 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GLP1R, IAPP | F2 580/4885P2RX7 2232/4885ITGB1 4242/4885 |
| US-11707507-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | IAPP, INSR, GLP1R | F2 812/4885P2RX7 870/4885ITGB1 3493/4885 |
| US-10383920-B2 | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, IDE, INSR | F2 663/4885P2RX7 2937/4885ITGB1 2742/4885 |
| US-20170348396-A1 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, F7, GIPR | F2 636/4885P2RX7 1732/4885ITGB1 4480/4885 |
| US-20190274953-A1 | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | GPR119, INSR, GCG | F2 1977/4885P2RX7 1394/4885ITGB1 3828/4885 |
| US-10548952-B2 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, F7, GIPR | F2 636/4885P2RX7 1732/4885ITGB1 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.